A recent study by Kulkarni et al., 2023, evaluated the feasibility of using autologous CD56-positive cells (enriched NK cells) from haploidentical family donors exposed to autologous plasma with 2 μM arsenic trioxide and 500 U/mL of IL-2, as an adjunct treatment for patients with refractory Acute Myeloid Leukemia (AML) undergoing reduced-intensity stem cell transplantation. The gene discussed is NCAM1; the disease is acute myeloid leukemia.